Background {#Sec1}
==========

Pulmonary arterial hypertension (PAH) is a progressive disease that may affect women of childbearing age. This disease often leads to right ventricular failure and death during pregnancy or after delivery \[[@CR1], [@CR2]\]. Some physiological changes during pregnancy can increase pulmonary vascular resistance (PVR) and precipitate right ventricular failure. For these reasons, the mortality rate of PAH during pregnancy is high \[[@CR3], [@CR4]\]. However, in recent years, the availability of better care and a multidisciplinary approach have decreased mortality \[[@CR1], [@CR5], [@CR6]\]. In this report we describe a 30-year-old pregnant woman with PAH who successfully delivered a healthy baby at 39 weeks of gestation without receiving treatment for pulmonary hypertension during her pregnancy.

Case presentation {#Sec2}
=================

Our patient is a 30-year-old primigravida Caucasian housewife who was referred to a cardiologist because of palpitations. Her medical history was unremarkable. She was not taking any medication and had negative history for tobacco smoking and drinking. Her family history was negative for pulmonary hypertension, systemic hypertension, and diabetes. After getting an echocardiogram, she was diagnosed as having severe pulmonary hypertension. A physical examination revealed that she had a loud pulmonic valve closure (P2) and grade 2/6 systolic murmur on the left sternal border. There was no pitting edema in lower extremities and no clubbing. She had normal pulses in all four extremities. Her oxygen saturation (O~2~ sat) was 91% in room air, and heart rate (HR) was 85 beats per minute at rest. Her blood tests for antinuclear antibodies (ANA), anti-centromere antibodies (Ab), anti-topoisomerase Ab, and human immunodeficiency virus Ab (HIVAb) were all negative. Thyroid function tests---thyroxin (T~4~), triiodothyronine (T~3~), and thyroid-stimulating hormone (TSH)---were normal. She had a normal kidney function test: creatinine (Cr) of 0.7 Mg/dL. Her liver enzymes were normal: aspartate aminotransferase (AST) of 26 U/L and alanine aminotransferase (ALT) of 28 U/L. She had normal urinalysis. In a 6-minute walk test (6MWT) she was able to walk 450 meters without a drop in her O~2~ sat.

She underwent right ventricle catheterization (Table [1](#Tab1){ref-type="table"}). Her vasoreactivity testing with adenosine was positive at 200 ug/minute. She was put on warfarin and amlodipine. In spite of strong advice against pregnancy, she became pregnant 6 months later and stopped taking her medications. In the first prenatal care visit, during the second trimester, she was in good general condition and did not have any complaints including dyspnea. On physical examination, P2 was loud, HR was 89/minute, O~2~ sat was 95%, and there was no edema of lower extremities. In 23rd week of pregnancy she was started on enoxaparin at 40 mg/day subcutaneously. In subsequent visits, her general condition stayed acceptable. She stayed symptom free except for some palpitations during activity. In the third trimester (month 8), she had another echocardiography (Table [2](#Tab2){ref-type="table"}).Table 1Right-side heart catheterization 6 months before pregnancySystemic BP 100/60 (73) mmHg100/60 (73) mmHgHeart rate78/minuteCVP6 mmHgRight atrium8 mmHgRight ventricular pressure72/10 (36) mmHgPulmonary artery pressure72/45 (60) mmHgPAWP11 mmHgCardiac output (thermodilution)4 liter/minuteCardiac index2.31 liter/minute per m^2^PVR (dyne × second/cm^5^)980 (12.2 WU)SVR (dyne × second/cm^5^)1346 (16.8 WU)Vasoreactive test (200 μg/kg per minute adenosine)Mean. PAP = 38 mmHg, cardiac output = 4.2 liter/minute*BP* blood pressure, *CVP* central venous pressure, *PAP* pulmonary arterial pressure, *PAWP* pulmonary artery wedge pressure, *PVR* pulmonary vascular resistance, *SVR* systemic vascular resistanceTable 2Echocardiography during pregnancy26 weeks37 weeksIVC21 mm22 mmTAPSE18 mm18 mmTRG103 mmHg80 mmHgRV free wall thickness10 mm11 mmRVSP113 mmHg100 mmHgLVEDD41 mm39 mmLVESD20 mm23 mmMain PA32 mm39 mm*IVC* inferior vena cava, *LVEDD* left ventricular end diastolic diameter, *LVESD* left ventricular end systolic diameter, *PA* pulmonary artery, *RV* right ventricular, *RVSP* right ventricular systolic pressure, *TAPSE* tricuspid annular plane systolic excursion, *TRG* tricuspid regurgitation gradient

In 37th gestational week, enoxaparin was discontinued and our patient was put on subcutaneously administered heparin. She was admitted for elective delivery. On physical examination, her cranial nerves were intact, P2 was loud, blood pressure (BP) was 135/85, HR was 98, and temperature was 37.3 °C. Heparin was stopped 6 hours prior to delivery. She had her third echocardiogram during hospitalization and in the 37th week of gestation (Table [2](#Tab2){ref-type="table"}), which did not show any new findings.

During pregnancy, fetus growth and placenta were normal based on ultrasonography.

She had an elective cesarean section under general anesthesia in her 39th week of gestation. A live, healthy baby boy was delivered. His Apgar score was 9. The baby was 48 cm tall and weighed 2700 gram with head circumference of 32 cm. The baby continued to be healthy 1 year after delivery.

After successful delivery her hemodynamics stayed stable. Heparin infusion was continued and eventually she was bridged to warfarin. After a week, she was transferred to our general ward. She was discharged home 2 weeks after delivery in good condition. One month later, she was seen again. Her general condition was satisfactory, and dyspnea was observed as functional class (FC) 1. At 1-year follow up she was in FC 2. On physical examination, P2 was loud, HR was 78/minute, O~2~ sat was 93%, and there was no edema of lower extremities.

Discussion {#Sec3}
==========

In this case report we presented a 30-year-old primigravida woman with idiopathic PAH (iPAH) who had a successful full-term pregnancy. She did not take medication for pulmonary hypertension during pregnancy and delivered a healthy baby.

Pulmonary hypertension secondary to congenital heart disease or iPAH are important problems among women of childbearing age. Elevated PVR often leads to right ventricular failure and death if left untreated \[[@CR1], [@CR2]\]. Pregnancy makes many changes in the maternal cardiovascular system, beginning in the first trimester \[[@CR7], [@CR8]\]. These changes increase mortality and morbidity in patients with pulmonary hypertension. Since maternal cardiac output and blood volume can increase by 30 to 50% during the third trimester \[[@CR7], [@CR8]\], pregnancy is strongly discouraged in patients with PAH and, if pregnancy occurs, early termination is recommended \[[@CR9]\].

Hormonal changes during pregnancy can lead to accumulation of a significant amount of fluid in the interstitial space. Following delivery, this fluid is shifted to the maternal circulation system, causing an increase in preload and hypertension \[[@CR10]\]. Furthermore, during labor, uterine contractions could effectively add 500 cc of blood to pulmonary circulation \[[@CR11]\]. Also, during vaginal delivery, the Valsalva maneuver and pain can increase HR and vascular resistance. These physiological changes in the presence of pulmonary vascular disease may not be tolerated, and can lead to cardiorespiratory failure \[[@CR12], [@CR13]\].

In pregnant women, because of increased prostacyclin production during pregnancy, PVR is approximately 30% less compared to non-pregnant women \[[@CR1]\]. This helps better tolerance of large volume load in pulmonary circulation without significant elevation of pulmonary pressure in pregnant women \[[@CR14]\]. However, in women with pulmonary hypertension, this normal physiology is impaired. This leads to a further rise in pulmonary artery pressure because of increased cardiac output \[[@CR15]\]. Blood volume peaks between the 20th and the 32nd week of gestation \[[@CR14]\]. So, the deterioration of pulmonary hypertension during pregnancy occurs after the 20th week of gestation \[[@CR16], [@CR17]\]. Usually, delivery is planned between the 32nd and 34th week of the pregnancy \[[@CR4]\].

Data suggest that early termination of pregnancy is associated with lower maternal complications and hospital mortality \[[@CR18]\]. The mode of delivery and anesthetic management are a matter of debate. In general, increased PVR, marked decrease in venous retention, and myocardial depression should be avoided.

Some of the medication used for anesthesia may influence hemodynamics in patients with pulmonary hypertension \[[@CR19], [@CR20]\]. Many physicians do not suggest cesarean section as a delivery method in these patients \[[@CR21]\]. Vaginal delivery is usually associated with reduced risk of bleeding and infection, but cesarean section precludes prolonged labor and allows for the careful consideration of optimal anesthesia and its administration. Regional anesthesia is generally preferred over general anesthesia because regional anesthesia has less effect on systemic vascular tone and cardiac function \[[@CR22]\]. Maternal mortality may increase with general anesthesia \[[@CR21]\]. Approximately 70 to 75% of the patients are delivered under epidural anesthesia \[[@CR23]\]. Since our patient had stable hemodynamics at her 37th week of pregnancy, we decided to delay the delivery until week 39. The decision regarding time and delivery method depends on maternal hemodynamics and fetal health. An elective cesarean section under general anesthetic was planned and delivery took place without any complications. This is a rare case of iPAH with successful delivery after 38 weeks of pregnancy. Until the past decade, pregnant patients with PAH had a very high mortality rate and patients with PAH were strongly advised against pregnancy. In recent years, these patients experienced less mortality. A retrospective review study showed a 30% mortality rate in pregnant patients with iPAH, 36% in patients with Eisenmenger syndrome, and 56% in patients with PAH associated with other conditions \[[@CR23]\]. Another study which was published later, showed less mortality \[[@CR21]\]. In the later study many patients were treated with pulmonary vasodilators. A more recent study involving 26 women with PAH who were treated at 13 pulmonary hypertension centers from 2007 to 2010 showed high mortality but the mortality was lower than that found in former studies \[[@CR24]\]. It seems one of the major reasons for less mortality in the most recent study was PAH targeted therapy. In this study, the patients who died had very high PVR: from 1560 to 1928 dyn.second.cm^−5^. Patients with vasoreactive pulmonary hypertension had a better prognosis during pregnancy \[[@CR25]\].

Our patient had pulmonary hypertension with positive vasoreactivity. Also, she was in FC I with PVR around 980 dyn.second.cm^−5^. During pregnancy, she was well in FC I without any hemodynamic instability. She underwent cesarean section under general anesthesia in her 39th week of pregnancy and delivered a healthy baby. In previous studies, most patients delivered after 34 weeks \[[@CR26]\].

Conclusions {#Sec4}
===========

Based on studies during the past three decades, the risk of mortality in pregnant patients with PAH remains high. There is recent evidence showing reduced mortality, particularly in patients with well-controlled pulmonary pressure, low PVR, and positive vasoreactivity test results.

Nonetheless, because of limited data, there is no general agreement about the safety of pregnancy even in patients with well-controlled pulmonary hypertension. Overall, pregnancy should be discouraged in this population. Early termination of pregnancy should be considered in patients with severe PAH.
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